Skip to content
    Real-World Studies

    JCM, Vol. 15, Pages 7700: Comorbidity Burden and Cumulative Anti-HER2 Exposure Associated with Cardiac Dysfunction in Breast Cancer: A Real-World Cardio-Oncology Cohort

    Sonaglioni et alJournal of Clinical Medicine

    In a real-world, single-center cardio-oncology cohort evaluating 850 adult patients with breast cancer treated with HER2-targeted therapy over a 10-year period (mean follow-up of 2.0 years; range, 0.5–9.0 years), cancer-therapy-related cardiac dysfunction (CTRCD) was observed in 179 patients (21.1%). CTRCD was classified using the harmonized 2022 European Society of Cardiology and International Cardio-Oncology Society criteria based on left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (LV-GLS), and cardiac biomarkers.
    The clinical course of cardiac dysfunction was characterized by transient deterioration of LVEF and LV-GLS at nadir followed by substantial functional recovery during subsequent longitudinal monitoring, with clinically overt heart failure developing in only 2.9% of the cohort. Notably, established baseline parameters—including traditional cardiovascular risk factors, prior anthracycline treatment, tumor grade, baseline LVEF, and baseline LV-GLS—failed to show a statistically significant association with the development of CTRCD.
    Multivariable logistic regression demonstrated that global comorbidity burden and treatment duration were independent drivers of cardiotoxicity. Each one-point increment in baseline Charlson Comorbidity Index was associated with a 35% increase in the odds of CTRCD (adjusted OR 1.35; 95% CI, 1.12–1.63; p = 0.002), while each five additional cycles of anti-HER2 therapy conferred a 41% increase in risk (adjusted OR 1.41; 95% CI, 1.10–1.80; p = 0.006). Progressively higher rates of CTRCD were observed across higher comorbidity strata and treatment exposure tiers; however, the authors emphasize that the relationship with cumulative anti-HER2 cycles remains hypothesis-generating given potential susceptibility to time-dependent and reverse-causality bias.

    Key Takeaways

    • Cancer-therapy-related cardiac dysfunction (CTRCD) occurred in 21.1% of patients (179 of 850) receiving anti-HER2 therapy, presenting predominantly as mild and reversible dysfunction, while clinically overt heart failure developed in 2.9%.
    • Multivariable analysis identified higher baseline Charlson Comorbidity Index (adjusted OR 1.35 per one-point increase; 95% CI, 1.12–1.63; p = 0.002) and cumulative anti-HER2 exposure (adjusted OR 1.41 per five additional cycles; 95% CI, 1.10–1.80; p = 0.006) as independent predictors of CTRCD.
    • Conventional cardiovascular risk factors, prior anthracycline exposure, tumor grade, baseline left ventricular ejection fraction, and baseline global longitudinal strain were not significantly associated with CTRCD risk.
    Read the original sourceJournal of Clinical Medicine